https://ir.ostherapies.com/ https://ir.ostherapies.com/news-events https://ir.ostherapies.com/news-events/press-releases https://ir.ostherapies.com/news-events/ir-calendar https://ir.ostherapies.com/news-events/presentations https://ir.ostherapies.com/news-events/email-alerts https://ir.ostherapies.com/company-information https://ir.ostherapies.com/company-information/executive-team https://ir.ostherapies.com/company-information/contacts https://ir.ostherapies.com/company-information/faq https://ir.ostherapies.com/financial-information https://ir.ostherapies.com/financial-information/financial-results https://ir.ostherapies.com/financial-information/income-statement https://ir.ostherapies.com/financial-information/balance-sheet https://ir.ostherapies.com/financial-information/cash-flow https://ir.ostherapies.com/stock-data/quote https://ir.ostherapies.com/stock-data/charts https://ir.ostherapies.com/stock-data/historical-data https://ir.ostherapies.com/sec-filings https://ir.ostherapies.com/sec-filings/all-sec-filings https://ir.ostherapies.com/sec-filings/annual-reports https://ir.ostherapies.com/sec-filings/quarterly-reports https://ir.ostherapies.com/sec-filings/section-16-filings https://ir.ostherapies.com/corporate-governance https://ir.ostherapies.com/corporate-governance/board-of-directors https://ir.ostherapies.com/corporate-governance/board-committees https://ir.ostherapies.com/corporate-governance/governance-documents https://ir.ostherapies.com/contact-us https://ir.ostherapies.com/news-events/press-releases/detail/124/os-therapies-reports-second-quarter-2026-financials-and https://ir.ostherapies.com/news-events/press-releases/detail/123/os-therapies-granted-u-s-fda-type-c-statistical-methods https://ir.ostherapies.com/news-events/press-releases/detail/122/os-therapies-accepts-new-fda-meeting-request-to-review https://ir.ostherapies.com/news-events/press-releases/detail/121/os-therapies-third-quarter-2026-corporate-outlook https://ir.ostherapies.com/news-events/press-releases/detail/120/os-therapies-appoints-dr-craig-eagle-to-board-of-directors https://ir.ostherapies.com/news-events/press-releases/detail/119/os-therapies-provides-u-s-regulatory-update https://ir.ostherapies.com/news-events/press-releases/detail/118/os-animal-health-announces-peer-reviewed-publication-of https://ir.ostherapies.com/news-events/press-releases/detail/117/os-therapies-achieves-global-regulatory-alignment-on-design https://ir.ostherapies.com/news-events/press-releases/detail/116/os-therapies-achieves-statistically-significant-2-5-year https://ir.ostherapies.com/news-events/press-releases/detail/115/os-therapies-announces-the-publication-of-four-articles-on https://ir.ostherapies.com/news-events/press-releases/detail/114/os-therapies-to-attend-upcoming-medical-financial-and https://ir.ostherapies.com/news-events/press-releases/detail/113/os-therapies-reports-first-quarter-2026-financials-and https://ir.ostherapies.com/news-events/press-releases/detail/112/os-therapies-to-announce-first-quarter-2026-financials-on https://ir.ostherapies.com/news-events/press-releases/detail/111/os-therapies-appoints-industry-leader-dr-craig-eagle-as https://ir.ostherapies.com/news-events/press-releases/detail/110/os-therapies-announces-ema-initiates-rolling-review-of https://ir.ostherapies.com/news-events/press-releases/detail/109/os-therapies-schedules-ost-her2-pharmacodynamic-response https://ir.ostherapies.com/news-events/press-releases/detail/108/os-therapies-files-new-patent-application-covering https://ir.ostherapies.com/news-events/press-releases/detail/107/os-therapies-appoints-biotech-industry-luminary-robert https://ir.ostherapies.com/news-events/press-releases/detail/106/os-therapies-appoints-craig-eagle-md-as-strategic-advisor https://ir.ostherapies.com/news-events/press-releases/detail/105/os-therapies-completes-5-25m-registered-direct-offering https://ir.ostherapies.com/news-events/press-releases/detail/104/os-therapies-completes-submission-of-biomarker-clinical https://ir.ostherapies.com/news-events/press-releases/detail/103/os-therapies-granted-meetings-with-u-s-fda-u-k-mhra-ema https://ir.ostherapies.com/news-events/press-releases/detail/102/os-therapies-granted-emas-advanced-therapy-medicinal https://ir.ostherapies.com/news-events/press-releases/detail/101/os-therapies-announces-fda-ost-her2-type-d-meeting-elevated https://ir.ostherapies.com/news-events/press-releases/detail/100/os-therapies-provides-global-regulatory-update-for-ost-her2 https://ir.ostherapies.com/news-events/press-releases/detail/99/os-therapies-applauds-reauthorization-of-pediatric-priority https://ir.ostherapies.com/news-events/press-releases/detail/98/os-therapies-initiates-us-fda-bla-filing-for-ost-her2-in https://ir.ostherapies.com/news-events/press-releases/detail/97/os-therapies-announces-positive-biomarker-data-from-phase https://ir.ostherapies.com/news-events/press-releases/detail/96/os-therapies-announces-filing-form-s-1-of-os-animal-health https://ir.ostherapies.com/news-events/press-releases/detail/95/os-therapies-enters-into-warrant-inducement-agreements https://ir.ostherapies.com/news-events/press-releases/detail/94/os-therapies-provides-first-half-2026-corporate-outlook https://ir.ostherapies.com/news-events/press-releases/detail/93/os-therapies-announces-successful-type-c-meeting-with-us https://ir.ostherapies.com/news-events/press-releases/detail/92/os-therapies-announces-successful-pre-marketing https://ir.ostherapies.com/news-events/press-releases/detail/91/os-therapies-announces-fda-pdufa-waiver-ema-grants-union https://ir.ostherapies.com/news-events/press-releases/detail/90/os-therapies-receives-non-proprietary-name-daznelimgene https://ir.ostherapies.com/news-events/press-releases/detail/89/os-therapies-to-spinoff-os-animal-health-into-standalone https://ir.ostherapies.com/news-events/press-releases/detail/88/os-therapies-reports-third-quarter-2025-financial-results https://ir.ostherapies.com/news-events/press-releases/detail/87/os-therapies-announces-overall-and-event-free-survival-key https://ir.ostherapies.com/news-events/press-releases/detail/86/os-therapies-granted-final-type-c-meeting-by-u-s-fda-and https://ir.ostherapies.com/news-events/press-releases/detail/85/os-therapies-announces-statistically-significant-positive https://ir.ostherapies.com/news-events/press-releases/detail/84/os-therapies-provides-positive-ema-regulatory-update https://ir.ostherapies.com/news-events/press-releases/detail/83/os-therapies-to-participate-in-fall-2025-conferences-and https://ir.ostherapies.com/news-events/press-releases/detail/82/os-therapies-provides-ost-her2-uk-mhra-and-us-fda https://ir.ostherapies.com/news-events/press-releases/detail/81/os-therapies-to-participate-in-spotlight-panel-at-biofuture https://ir.ostherapies.com/news-events/press-releases/detail/80/os-therapies-announces-last-patient-enrolled-in-ost-504 https://ir.ostherapies.com/news-events/press-releases/detail/79/os-therapies-to-participate-in-upcoming-investor https://ir.ostherapies.com/news-events/press-releases/detail/78/os-therapies-provides-ost-her2-recurrent-fully-resected https://ir.ostherapies.com/news-events/press-releases/detail/77/os-therapies-completes-exercise-inducement-and-exchange https://ir.ostherapies.com/news-events/press-releases/detail/76/os-therapies-to-provide-ost-her2-recurrent-fully-resected https://ir.ostherapies.com/news-events/press-releases/detail/75/os-therapies-terminates-equity-line-of-credit https://ir.ostherapies.com/news-events/press-releases/detail/74/os-therapies-reports-second-quarter-2025-financial-results https://ir.ostherapies.com/news-events/press-releases/detail/73/os-therapies-to-report-second-quarter-2025-financial https://ir.ostherapies.com/news-events/press-releases/detail/72/os-therapies-announces-statistically-significant-positive https://ir.ostherapies.com/news-events/press-releases/detail/71/os-therapies-receives-positive-feedback-from-uk-mhra https://ir.ostherapies.com/news-events/press-releases/detail/70/os-therapies-closes-4-2-million-in-warrant-exercise https://ir.ostherapies.com/news-events/press-releases/detail/69/os-therapies-provides-clinical-global-regulatory-updates https://ir.ostherapies.com/news-events/press-releases/detail/68/os-therapies-granted-end-of-phase-2-meeting-by-us-fda-for https://ir.ostherapies.com/news-events/press-releases/detail/67/os-therapies-presents-statistically-significantly-positive https://ir.ostherapies.com/news-events/press-releases/detail/66/os-therapies-receives-positive-fda-meeting-feedback-on https://ir.ostherapies.com/news-events/press-releases/detail/65/os-therapies-announces-warrant-exercise-inducement https://ir.ostherapies.com/news-events/press-releases/detail/64/os-therapies-partners-with-eversana-for-the-u-s https://ir.ostherapies.com/news-events/press-releases/detail/63/os-therapies-submits-request-for-regenerative-medicine https://ir.ostherapies.com/news-events/press-releases/detail/62/os-therapies-reports-first-quarter-2025-financial-results https://ir.ostherapies.com/news-events/press-releases/detail/61/os-therapies-forms-subsidiary-os-animal-health-to https://ir.ostherapies.com/news-events/press-releases/detail/60/os-therapies-announces-issuance-of-u-s-patent-12239738 https://ir.ostherapies.com/news-events/press-releases/detail/59/emmy-winning-series-debuts-trailer-for-shelter-me-the https://ir.ostherapies.com/news-events/press-releases/detail/58/os-therapies-fda-meeting-request-granted https://ir.ostherapies.com/news-events/press-releases/detail/57/os-therapies-announces-positive-data-for-ost-her2-in-the https://ir.ostherapies.com/news-events/press-releases/detail/56/os-therapies-completes-acquisition-of-advaxis https://ir.ostherapies.com/news-events/press-releases/detail/55/os-therapies-requests-meeting-with-fda-to-gain-agreement-on https://ir.ostherapies.com/news-events/press-releases/detail/54/os-therapies-to-host-analyst-day-at-nyse-on-april-7-2025 https://ir.ostherapies.com/news-events/press-releases/detail/53/os-therapies-reports-full-year-2024-financial-results-and https://ir.ostherapies.com/news-events/press-releases/detail/52/os-therapies-provides-regulatory-update-on-rare-pediatric https://ir.ostherapies.com/news-events/press-releases/detail/51/os-therapies-ost-her2-immunotherapy-for-osteosarcoma https://ir.ostherapies.com/news-events/press-releases/detail/50/os-therapies-to-attend-the-jones-healthcare-and-technology https://ir.ostherapies.com/news-events/press-releases/detail/49/os-therapies-awarded-ost-her2-clinical-trial-data https://ir.ostherapies.com/news-events/press-releases/detail/48/os-therapies-schedules-united-kingdoms-medicines-and https://ir.ostherapies.com/news-events/press-releases/detail/47/join-os-therapies-exclusive-live-investor-webinar-and https://ir.ostherapies.com/news-events/press-releases/detail/46/os-therapies-forms-subsidiary-os-drug-conjugates-and https://ir.ostherapies.com/news-events/press-releases/detail/45/os-therapies-receives-patent-notice-of-allowance-from-u-s https://ir.ostherapies.com/news-events/press-releases/detail/44/os-therapies-initiates-commercial-ready-manufacturing-of https://ir.ostherapies.com/news-events/press-releases/detail/43/os-therapies-provides-corporate-update https://ir.ostherapies.com/news-events/press-releases/detail/42/os-therapies-agrees-to-acquire-all-listeria https://ir.ostherapies.com/news-events/press-releases/detail/41/os-therapies-announces-phase-2b-clinical-trial-of-ost-her2 https://ir.ostherapies.com/news-events/press-releases/detail/40/os-therapies-to-attend-the-43rd-annual-j-p-morgan https://ir.ostherapies.com/news-events/press-releases/detail/39/os-therapies-announces-closing-of-6-million-private https://ir.ostherapies.com/news-events/press-releases/detail/38/os-therapies-partners-with-b2i-digital-to-engage-with https://ir.ostherapies.com/news-events/press-releases/detail/37/os-therapies-announces-pricing-of-6-million-private https://ir.ostherapies.com/news-events/press-releases/detail/36/os-therapies-reports-third-quarter-2024-financial-results https://ir.ostherapies.com/news-events/press-releases/detail/35/os-therapies-to-present-at-the-spartan-capital-investor https://ir.ostherapies.com/news-events/press-releases/detail/34/join-os-therapies-exclusive-live-investor-webinar-and https://ir.ostherapies.com/news-events/press-releases/detail/33/os-therapies-appoints-two-bio-pharmaceutical-industry https://ir.ostherapies.com/news-events/press-releases/detail/32/os-therapies-to-present-at-the-ld-micro-main-event-xvii https://ir.ostherapies.com/news-events/press-releases/detail/31/os-therapies-to-participate-in-a-fireside-chat-at-the-2024 https://ir.ostherapies.com/news-events/press-releases/detail/30/os-therapies-announces-last-patient-enrolled-in-ost-her2 https://ir.ostherapies.com/news-events/press-releases/detail/29/os-therapies-announces-development-of-two-novel-tunable https://ir.ostherapies.com/news-events/press-releases/detail/28/os-therapies-announces-positive-efficacy-and-safety-data https://ir.ostherapies.com/news-events/press-releases/detail/27/os-therapies-to-present-at-h-c-wainright-26th-annual https://ir.ostherapies.com/news-events/press-releases/detail/26/os-therapies-announces-last-patient-enrolled-in-ost-her2 https://ir.ostherapies.com/news-events/press-releases/detail/25/os-therapies-appoints-borys-shor-phd-to-adc-advisory-board https://ir.ostherapies.com/news-events/press-releases/detail/24/os-therapies-clarifies-cusip-of-common-stock https://ir.ostherapies.com/news-events/press-releases/detail/23/os-therapies-accepted-into-johnson-johnson-innovation- https://ir.ostherapies.com/news-events/press-releases/detail/22/os-therapies-reports-second-quarter-2024-financial-results https://ir.ostherapies.com/news-events/press-releases/detail/21/os-therapies-announces-osteosarcoma-scientific-and-medical https://ir.ostherapies.com/news-events/press-releases/detail/20/os-therapies-forms-osteosarcoma-patient-advocacy-advisory https://ir.ostherapies.com/news-events/press-releases/detail/19/os-therapies-announces-pricing-of-its-initial-public https://ir.ostherapies.com/news-events/press-releases/detail/18/os-therapies-announces-positive-safety-data-from-phase-1 https://ir.ostherapies.com/news-events/press-releases/detail/17/os-therapies-announces-positive-clinical-update-from https://ir.ostherapies.com/news-events/press-releases/detail/5/team-arnav-foundation-partners-with-os-therapies-supporting https://ir.ostherapies.com/news-events/press-releases/detail/6/os-therapies-announces-nationwide-open-enrollment-of https://ir.ostherapies.com/news-events/press-releases/detail/7/os-therapies-receives-rare-pediatric-disease-designation https://ir.ostherapies.com/news-events/press-releases/detail/8/os-therapies-announces-dosing-of-first-patient-in-a-phase https://ir.ostherapies.com/news-events/press-releases/detail/9/childrens-cancer-research-fund-supports-aost-2121-phiib https://ir.ostherapies.com/news-events/press-releases/detail/10/os-therapies-completes-6-million-series-a-funding-round https://ir.ostherapies.com/news-events/press-releases/detail/11/os-therapies-receives-trial-approval-from-childrens https://ir.ostherapies.com/news-events/press-releases/detail/12/os-therapies-acquires-all-indications-for-ost-her2 https://ir.ostherapies.com/news-events/press-releases/detail/13/fda-transfers-investigational-new-drug-ind-application https://ir.ostherapies.com/news-events/press-releases/detail/14/dr-jutta-wanner-joins-her-next-generation-adc-technology https://ir.ostherapies.com/news-events/press-releases/detail/15/os-therapies-to-develop-blinkbio-next-generation-antibody https://ir.ostherapies.com/news-events/press-releases/detail/16/dr-robert-petit-follows-his-passion-to-os-therapies-as https://ir.ostherapies.com/privacy-policy https://ir.ostherapies.com/disclaimer https://ir.ostherapies.com/sitemap